751家私募6月调研387家A股公司电子、医药生物行业最受青睐

Group 1 - Private equity funds are actively conducting research, with 751 private equity managers conducting 1,769 surveys on 387 A-share listed companies in June, indicating a strong interest in the market [1][2] - The electronic and pharmaceutical industries are the most favored by private equity, with a total of 541 surveys conducted in these sectors, accounting for over 30% of the total [1][3] - Maiwei Biotech emerged as the most popular stock among private equity, receiving 51 surveys, driven by its collaboration with Calico on anti-aging research [2][3] Group 2 - The electronic industry had 56 stocks receiving a total of 275 surveys, making it the most researched sector, while the pharmaceutical industry had 41 stocks with 266 surveys [3] - The top five private equity firms conducting the most surveys in June were Zhengyuan Fund, Pankin Investment, Shangcheng Asset, Danshuiquan, and Qingli Investment, with Zhengyuan Fund leading at 39 surveys [4] - Star Stone Investment believes that the current market structure needs to change, as the performance of small-cap stocks and dividend stocks is not sustainable [5][6] Group 3 - The "anti-involution" policies are being implemented across various sectors, which is expected to stabilize production capacity and end the prolonged profit decline for listed companies [6] - The overall market risk premium remains high, and the total market value to household deposits is at a historical low, indicating potential for long-term revaluation of A-shares [6] - Opportunities in industries such as artificial intelligence, autonomous driving, and new consumption are emerging, with a focus on mid-level industry opportunities and bottom-up stock selection [6]